Follitropin delta - Ferring Pharmaceuticals
Alternative Names: FE-999049; Recombinant follicle-stimulating hormone - Ferring Pharmaceuticals; Recombinant FSH - Ferring; RekovelleLatest Information Update: 14 Jun 2024
At a glance
- Originator Ferring Pharmaceuticals
- Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
- Mechanism of Action Ovarian follicle stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Female infertility
- Preregistration Male infertility
Most Recent Events
- 16 Apr 2024 Ferring Pharmaceuticals completes a phase III ADAPT-1 trial for Female infertility (Combination therapy) in Austria, France, Germany, Italy, Spain and United Kingdom (SC) (EudraCT2021-001785-38) (NCT05263388)
- 29 Mar 2024 Ferring Pharmaceuticals initiates the phase III COCO trial in Female infertility in China (SC) (NCT06173869)
- 02 Jan 2024 Preregistration for Female infertility in USA (SC), before January 2024 (Ferring Pharmaceuticals pipeline, January 2024).